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Abstract 
 
In this Special Issue on “Nutraceuticals: Molecular and Functional Insights into how Natural 
Products Nourish the Brain”, the editors bring together contributions from experts in 
nutraceutical research to provide a contemporary overview of how select chemically 
identified molecules can beneficially affect brain function at the molecular level. Other 
contributions address key emergent issues such as bioavailability, formulation, blood brain 
permeability, neuronal health and inflammation that impact upon how nutraceuticals 
ultimately leverage the brain to function better. Whilst nutraceutical is used as marketing 
term, it has no regulatory definition, and there is a continuing need for licensing authorities to 
ensure that adequate guidelines exist pertinent to the safety to guide consumers 
internationally. In terms of the benefit of nutraceuticals is it clear that some naturally 
occurring molecules can be advantageous to both the young and aged brain, and that they 
have actions that ultimately can be directed to aid either in the improvement of cognition or 
in the management of debilitating neurodegenerative and neuropsychiatric conditions. 
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This Special Issue grew out of the awareness of the Editors that the basic and clinical 
research underpinning how nutraceuticals improved brain function during development, 
ageing and disease was growing in quality such that the focus was increasingly on cellular 
and molecular targets that ultimately leveraged improved brain function. What is truly 
amazing is the spectacular recent growth of interest in this topic from a neuro-perspective 
given the overall surprising lack of endeavour targeting the brain relative to the nutraceutical 
field in general. A PubMed search for nutraceuticals turns up more than 50,000 articles, but 
less than 2,000 of these are linked to the brain. However, encouragingly some 50% of these 
latter publications addressing brain function have appeared in the last five years. Everyone is 
living longer, dementia and Alzheimer’s disease threaten, and people the world over want to 
enjoy life in their latter years. Keeping the brain healthy by use of natural products, 
increasingly advocated by nutritionists, proponents of alternative medicine, the popular press 
and social media, thus emerges as a goal the populace at large wants to achieve. 
 
Nutraceutical is a term coined in 1989 by Dr. Stephen L. De Felice (Founder and Chairman 
of the Foundation for Innovation in Medicine, New Jersey, USA) from nutrition and 
pharmaceutical. The Nutraceutical Research and Education Act (1999) of USA seeks to 
‘promote research into the health benefits of dietary supplements, medical foods, and other 
foods. It demands sound scientific evidence of safety and effectiveness in order to fulfil its 
statutory mandate to protect and promote the public health’. Nutraceuticals represent 
vitamins, amino acids, minerals, trace elements, etc. which consists of about 60 groups of 
compounds identified so far. Within the nutraceutical category there are more than 1000 
compounds, and typical examples include resveratrol from grapes, genistein from soy 
proteins, lutein from kiwi fruit and broccoli, lycopene from tomatoes, bromelain from 
pineapple, and organosulphur compounds from Allium vegetables (e.g. garlic, onion, leeks; 
Powolny & Singh, 2008).  
 
Whilst a key aim herein was to focus on investigations of chemically identified molecules 
isolated from traditional medicines, a further aim was to overview the background and 
modern horizons of how nutraceuticals might be used to sustain brain health in daily life and 
during debilitating pathologies. We also sought to provide an overview of the limitations to 
the exploitation of nutraceuticals and to give some proper consideration to the metabolism, 
bioavailability and blood brain permeability of molecules that might exert beneficial actions 
on brain. The editors in assembling this Special Issue, “Nutraceuticals: Molecular and 
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Functional Insights into how Natural Products Nourish the Brain”, recognized that the time 
was right for an overview of this expanding field. However, the project has grown so rapidly, 
with incredible enthusiasm from authors internationally, that the issue will now be published 
as two parts with the second volume appearing in early 2016. Overall, we hoped this Special 
Issue would provide a timely overview of this emerging field and map key future directions 
for neuro-nutraceutical research. 
 
Nutraceuticals - some historical perspective 
 
In hindsight, the in vogue acceptance and pre-eminence of nutraceutical related research is 
not surprising. As suggested above, we all want or seek to improve brain health be it in aging 
or disease. The Oxford Dictionary defines “nutraceutical”, a term derived from both nutrition 
and pharmaceutical, as “another term for functional food” with functional food being “a food 
containing health-giving additives”. Basically, any part of a food providing health benefits, 
including the prevention and/or treatment of disease. From the perspective of prehistoric 
medicine in the ancient world on all continents, plants have been used in the treatment of 
medical conditions through human history. Historically, one can trace a path linking 
apothecary, herbalism, ethnopharmacology, phytotherapy, and alternative medicine to 
nutraceuticals. In some cultures the primitive concept of prevailing illness was seen as a 
punishment of the gods and the evolution of therapy often had both “magical” and 
“instinctive” components involving both vegetables and medicinal plants, and remedies of 
animal and mineral origins (Albarracin, 1985). Of course, European herbal medicine and 
therapeutic methods benefited greatly from the transfer of traditional knowledge from Asia, 
the Middle East and the Americas. With the rational use of medicines the apothecarist 
became a pharmacist and eventually the principles of drug action, therapeutics and modern 
drug development with clinical trials ensued. In hindsight it is interesting to recall that drug is 
from the French “drogue” meaning dried herb. Nevertheless, such “traditional medicine” 
continues today. 
 
The history of the Indian tradition on healing art is rich in varied traditional healing 
procedures; roughly Ayurveda, Unani, Siddha and Ashtavaidya systems of medicine merging 
into the major ones. Ancient texts of classical Ayurveda are Charaka Samhita, Susrutha 
Samhita and Ashtangahrdayam, which date back to 371 – 287 BC (Menon and Spudich, 
2010). A Traditional Knowledge Digital Library (TKDL) was created by the Council of 
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Scientific and Industrial Research, Government of India, to provide information on traditional 
knowledge existing in the country, in languages and format understandable widely (Chaudhry 
and Singh, 2012; Kidd, 2012). Not surprisingly, there was a similar tradition in China and the 
Compendium of Materia Medica, also known as Bencao Gangmu or Pen-tsao Kang-mu, is a 
Chinese materia medica work written by Li Shizhen during the Ming Dynasty. The 
Compendium of Materia Medica is regarded as the most complete and comprehensive 
medical book ever written in the history of traditional Chinese medicine, consisting of 1,892 
entries. It lists all the plants, animals, minerals, and other items that were believed to have 
medicinal properties. Li Shizhen completed the first draft of the text in 1578, after conducting 
readings of 800 other medical reference books and carrying out 30 years of field study (Yaniv 
and Bachrach, 2005). Chinese herbal medicine was transferred to and further developed in 
Japan becoming Kampō medicine, which has aspects relevant to the management of nervous 
system conditions. Interestingly, some herbal medicines in Japan are regulated as 
pharmaceutical preparations and integrated into the Japanese national health care system 
(Sugaya et al., 1997). 
 
So where did neuro-nutraceutical research begin in modern neuroscience? Indeed here, it is 
hard to go past the almost legendary publications by Jim Joseph and colleagues (Joseph et al., 
1998, 1999) describing behavioural and cognitive improvements after blueberry, spinach, or 
strawberry dietary supplementation. Having heard the late Jim Joseph speak, his charismatic 
style of presentation engendered great enthusiasm in the audience such that one would want 
to add neuro-nutraceuticals to your diet. Joseph’s background in neurochemical 
pharmacology represented a solid launching pad for his work and made him very conscious 
of the role of oxidative stress in brain injury and neurodegenerative conditions. His work 
mentions the earlier success of increased dietary vegetables and fruit rich in antioxidant 
activity in reducing the incidences of ischemic heart disease and cancer. Additionally, there is 
also reference to the diversity of potentially bioactive molecules contained in vegetables and 
fruit, noting the presence of various phytonutrient antioxidants, including flavonoids. In 
hindsight, the initial focus upon antioxidant activity is hardly surprising as at this time 
oxidative stress was receiving massive attention as a causative mechanism in brain 
pathologies (Simonian and Coyle, 1996; Higgins et al., 2010). Indeed flavonoids have long 
attracted much attention in human nutrition and Kuhnau (1976) in his classical review noted 
their mention relevant to vitamin research by Nobel Prize winner Szent-Gyorgi and 
colleagues (Bentsath et al., 1936). Interestingly, at the time of publication of Joseph’s work, 
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Catherine Rice-Evans across the Atlantic in London was attacking flavonoid biology after 
many years of experience in probing their chemistry and subsequently published notable 
accounts with neurochemical colleagues of their neuroprotective ability versus injury in 
cultured neurons (Schroeter et al., 2000 & 2001). 
 
Diverse actions of nutraceuticals 
 
Nutraceutical related research of molecular actions follows from the concept that traditional 
medicines or tribal practices offer nutritious agents that cure diseases. The goal then is to 
elucidate how bioactive molecules from these sources might make the brain healthier and in 
this volume we have a number of exciting basic studies that represent the prototype of how 
this field needs to evolve. For example, geniposide (contained in Gardenia fruit; Chinese 
medicine) attenuates insulin-deficiency-induced acceleration of β-amyloidosis in an APP/PS1 
transgenic model of Alzheimer's disease (Zhang et al.). Neuroinflammation plays a prominent 
role in the pathophysiology of many neurological conditions and is considered a genuine 
therapeutic target by the pharmaceutical industry, so it is hardly surprising that the search for 
novel anti-inflammatory agents continues apace amongst nutraceuticals. Oxymatrine 
(derived from root of Sophora; Chinese herb), reported to have anti-inflammatory actions, 
elevates anti-oxidant mechanisms with consequent decreases in the extent of damage 
observed after hypoxic-ischaemic brain injury (Zhao et al.). Apocynin (root of Picrorhiza 
kurroa (Scrophulariaceae); traditional Indian medicine (Ayurveda)), also believed to have 
anti-inflammatory actions, was found to attenuate the cholesterol oxidation product-induced 
programmed cell death in neuronal cells by preventing production of reactive oxygen species 
and depletion of glutathione (Lee et al.). Curcumin (Curcuma longa; traditional Indian & 
Chinese medicine) produced beneficial effects in chronic epilepsy by attenuating glial 
activation and suppression of the activation of cytokines and chemokines (Kaur et al.). 
Flavonoids and polyunsaturated fatty acids (eicosapentaenoic and docosahexaenoic acids) 
alleviate the inflammatory response of activated microglial cells and these anti-inflammatory 
actions appear to be beneficial in modulating age-related memory decline (Vauzour et al.). 
Resveratrol has a similar action against microglial activation, although multiple actions on 
silent information regulator 1 (SIRT1), AMP-activated kinase (AMPK) and nuclear factor 
(erythroid derived 2)-like 2 (Nrf2) may contribute to its beneficial effects in models of 
ischemic stroke and traumatic brain injury (Lopez et al.). Garlic (Allium sativum) has long 
been considered a remedy for human diseases and S-allyl cysteine, the most abundant 
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compound in aged garlic extracts, has various neuroprotective actions likely mediated by 
anti-oxidant actions perhaps via Nrf2, but more recent observations suggest additionally a 
panoply of anti-inflammatory effects (Colin-Gonzalez et al.). Allicin, another component of 
garlic, effectively blocked neuronal injury via an action on sphingosine kinase 2 and 
demonstrated protective effects in a rat model of middle cerebral artery occlusion even after 
delayed administration (Lin et al.). Crocin, a plant colouring pigment (Crocus sativus) 
previously shown to possess anti-inflammatory actions, was found to attenuate endoplasmic 
reticulum stress in a cellular model of Parkinson’s disease (Zhang et al.). Finally, 
Ashwagandha (Withania somnifera) has been extensively employed in traditional medicines 
as an aphrodisiac and it led to the upregulation of release and expression of gonadotrophin-
releasing hormone supporting its use as a preparation for improvement of sexual performance 
and fertility (Kataria et al.). 
 
Flavonoids – old nutraceuticals but much interest in new actions 
 
In reality, it was no surprise that the actions of flavonoid-like molecules attracted much 
attention since these are well documented to have neuroprotective actions be it through their 
diverse actions, including those as free radical scavengers and/or activators of key signalling 
cascades (Mercer et al., 2005; Williams et al., 2004). Despite significant advances in our 
understanding of the biology of flavonoids over the past 15 years they are still mistakenly 
regarded by many as acting simply as antioxidants yet flavonoids exert modulatory effects in 
cells independent of classical antioxidant capacity through selective actions at different 
components of a number of protein kinase and lipid kinase signalling cascades. Furthermore, 
flavonoids exert actions on mitochondria, interfere with pathways of intermediary 
metabolism and there is good evidence for specific flavonoid interactions with GABAA 
receptors (Johnston). Indeed work during the 1990s drew attention to flavonoids as ‘a new 
family of benzodiazepine receptor ligands’, but flavonoids possess at least two distinct 
mechanisms via a variety of sites in the GABAA receptor (Johnston). With respect to 
potentially protective actions in dementia, flavonoids are likely to combat neuronal 
dysfunction and toxicity by recruiting anti-apoptotic pro-survival signalling pathways, 
increasing antioxidant gene expression, and reducing amyloid β (Aβ) pathology (Williams et 
al., 2004; Williams and Spencer, 2012; Cox et al., 2015). There is however, a lack of 
consensus as to the precise identities of the flavonoids capable of exerting these effects, 
partly because flavonoids have poor bioavailability and are extensively metabolised in vivo, 
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but also because most in vitro studies use concentrations that are at least 100 times higher 
than those found following dietary administration. Alternatively or concurrently, there is 
emerging and compelling evidence derived in part from human studies suggesting that 
flavonoids can positively affect peripheral and cerebrovascular blood flow (Rendeiro et al.) 
and this indirect mechanism influencing neurovascular coupling may explain some of the 
observed effects of flavonoids on plasticity and cognition, even in the absence of good brain 
bioavailability.  
 
Quercetin, found in vegetables and fruit, potentially has both pro- and anti-oxidant actions, 
with the latter effects eliciting redox regulation of proteins, transcription factors and a broad 
range of kinase-dependent signalling cascades, some of which are linked to cellular survival 
mechanisms (Dajas et al.). Complex absorption and metabolic steps after oral intake make it 
likely that nutraceutical additive actions of quercetin will be best served by its pharmaceutical 
formulation to expedite optimal delivery and such a preparation effectively produced 
recovery of brain activity with improved breathing, motor and feeding behaviour in perinatal 
hypoxia (Blasina et al.). In a landmark study (Janssen et al.), undertook the first detailed 
examination of perinatally supplemented dietary flavonoids during the gestational and 
postnatal period on brain structure, cerebral blood flow, cognition, and brain metabolism in 
mice. There were subtle alterations in brain structure, locomotor activity and spatial learning, 
suggesting that the benefits of dietary flavanols may increase with advancing age. The 
naturally occurring BDNF-mimetic, flavonoid 7,8-dihydroxyflavone (Godmania 
aesculifolia, Tridax procumbens, primula leaves), rescues cognitive deficits and may 
represent a novel treatment for schizophrenia, autism, Rett syndrome and foetal alcohol 
disorder (Du and Hill). Over the years many studies have examined the potential benefits of 
the consumption of tea, which contains various flavonoids, and the major green tea 
component (-)epigallo-catechin 3-gallate (EGCG) efficiently crosses the blood brain barrier - 
these polyphenols are active in cellular and animal models of Parkinsonism suggesting green 
tea may be considered as an anti-Parkinsonian, natural-origin beverage (Dutta and 
Mohanakumar). 
 
Emergent issues: bioavailability and the concept of one molecule with multiple 
Nutraceutical actions  
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Indeed for polyphenols in general, including quercetin, improving bioavailability entails 
efficient in vivo transport across the blood-brain-barrier and biochemical stability with 
improved half-life via modern drug delivery approaches considered essential for optimal 
efficacy in brain (Pandareesh et al.). The application of nanotechnologies to clinical 
neuroscience is in its infancy, but nano-enabled drug delivery systems pass through the blood 
brain barrier and improve delivery of drugs such as natural antioxidants to the central nervous 
system to allow therapeutic management of neurodegenerative conditions (Sandhir et al.). 
Trans-resveratrol and pterostilbene are two nutraceuticals where improved bioavailability 
would also be beneficial as these promising bioactive agents improve brain health, having 
diverse actions against oxidative stress and inflammation, and appear from clinical trials to be 
relatively well tolerated (Poulose et al.). In this volume we feature two articles where the 
investigators have succeeded in using contemporary drug delivery methods to deliver 
nutraceuticals - drug delivery via nanoparticles and related technologies is certainly a way 
forward to achieve adequate brain concentrations of potentially advantageous nutraceuticals. 
Thus Blasina et al. achieved an impressive beneficial outcome in perinatal hypoxia with a 
nanosomal delivery of quercetin. Curcumin micelles prevented mitochondrial dysfunction 
and improved its bioavailability some 10-40 fold in murine plasma and brain relative to 
native curcumin (Hagl et al.). 
 
Modern drug development is strongly focused on the guiding principle that a drug should 
possess just one site of action, with little or no additional effects that might compromise its 
selectivity. However, the literature is full of examples where clinical approved drugs act upon 
multiple targets and many attempts have been made to develop pharmaceuticals that are bi-
functional in their actions. Here it may be worth re-interpreting the view of Joseph et al. 
(1998) that “the whole is more than the sum of its parts” i.e. maybe it is not the overall 
actions of multiple nutraceuticals in a functional food that provide health benefits and treat a 
disease condition, but the multiple beneficial actions of a single “effective” nutraceutical? In 
the modern context of the molecular and cellular neuroscience of neurodegenerative 
conditions and brain injury, not only are multiple mechanisms involved (e.g. oxidative stress, 
excitotoxicity, protein aggregation, disturbed proteostasis, etc and their downstream effects), 
but neuronal injury is accompanied by inflammation (recruitment of micro-/macroglial 
signalling), and altered cerebral blood flow in concert with changes in the blood-brain-barrier 
(see Fig. 1). So it would not seem heretical to propose that one naturally occurring and 
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bioavailable substance in a mix of potentially bioactive molecules might have multiple 
ameliorative actions on brain function and/or pathology by interacting with multiple targets. 
 
Thus in this context, flavonoids can positively affect peripheral and cerebrovascular blood 
flow, which may represent an indirect mechanism by which dietary flavonoids could impact 
upon brain function. Here improved efficacy of cerebrovascular coupling could potentially 
increase neuronal activation and synaptic plasticity leading to improvements in cognitive 
ability – indeed cerebral blood perfusion declines in aging and other neurological disorders 
(Rendeiro et al.). In related, novel work fisetin, known to have many central actions (direct 
anti-inflammatory & antioxidant activities, increases glutathione, activates neurotrophic 
signalling), was shown by fluorescence imaging in living mice after peripheral administration 
to be rapidly distributed to blood vessels of the brain followed by a slower dispersion into the 
brain parenchyma (Krasieva et al.). Some phytochemicals activate adaptive stress response 
pathways, which are also recruited by exercise and energy restriction, implying these 
molecules may improve brain health and reduce the risk of neurodegenerative disorders. 
Emerging evidence suggest that neurohormetic phytochemicals can enhance removal of 
proteopathic proteins by activation of pathways that minimize oxidative damage and bolster 
bioenergetics (Murugaiyah and Mattson). The interface of nutraceuticals with brain 
bioenergetics is an emerging issue worthy of attention. Boosting energetics may improve 
cognitive function and creatine, long known to have nutraceutical-related actions 
(Wallimann, 2007), appears to have the potential for cognitive enhancement, particularly in 
conditions where baseline bioenergetics are compromised (Rae and Broer). Relevant to the 
issues introduced above, Ng et al. also make the point that some naturally occurring alkaloids 
(and nutraceuticals) may be beneficial since the sum of their actions may arise from multiple 
targets. Indeed, in this context promising clinical results of galantamine and memantine 
combination therapy support multi-target-directed ligands as a new treatment strategy for 
etiologically complex diseases such a neurodegenerative conditions. These authors found that 
although rhynchophylline had multiple pharmacological actions, its potency as an inhibitor 
of the receptor tyrosine kinase EphA4 translated to rescue of hippocampal synaptic 
dysfunction in a mouse model of Alzheimer’s disease AD (Fu et al., 2014). So seemingly the 
multiple beneficial actions of a single nutraceutical can improve brain health, but the 
important corollary is that there should be scientific evidence of safety. 
 
Nutraceuticals, their promise and regulatory issues 
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The National Center for Complementary and Integrative Health of the National Institutes of 
Health (USA) conducted a nationwide survey on American children’s use of natural products 
such as melatonin, Echinacea, probiotics, as well as on the use of mind and body approaches 
of yoga, chiropractic, massage, and complementary health approaches between 2007 and 
2012. The survey revealed natural product use in the United States has shifted since 2007, 
with certain products such as fish oil and melatonin more popular, and some such as 
glucosamine/chondroitin, echinacea, and garlic, being dropped. Fish oil use was the top 
natural product among adults, and children, followed by melatonin, the use of which 
increased substantially from 2007 to 2012 (http://nccih.nih.gov/NHIS2012). 
 
There are limitations and worries about the use of nutraceuticals, which are widely available, 
but loosely regulated. They are not strictly under any regulations unlike pharmaceuticals, and 
therefore business houses may create undesirable products for consumption for selfish gains. 
Low bioavailability is another worry (vide supra), which is heightened when low doses are 
recommended for nutraceuticals which are noxious chemicals termed as “neurohormetic 
phytochemicals” (Murugaiyah and Mattson). Lack of scientific validation, overzealous 
marketing gimmicks, wide media support, etc are other public concerns. Animal studies and 
clinical reports are available for adverse reactions, and reactions following multidrug 
interactions. Typical cases are allylisothiocyanate, a nutraceutical acting as a carcinogen in 
higher doses (National Toxicology Program, 1982; Waddell, 2003), and an unusual adverse 
effect of a nutraceutical containing tiratricol causing paralysis (Cohen-Lehman et al., 2011). 
 
One issue for regulatory authorities is that commercially available products claimed as 
possessing “nutraceutical activity” do not generally undergo traditional randomized, placebo 
controlled, blinded clinical trials and thus proper consideration has not been given either to 
toxicology or to the pharmacokinetics including metabolism and bioavailability. Moreover, 
many nutraceuticals could be considered as undefined extracts wherein the molecular actions 
and targets, and their “drug interactions” are undefined. This creates a significant problem as 
in some cases it is resulting in the indiscriminate marketing of food supplements and 
nutraceuticals on the basis of unproven neuroprotective effects, and positive health claims 
have been made about nutraceuticals and supplement that have extremely poor brain 
bioavailability. Indeed, it is notable that there are no preventative nutraceutical 
recommendations for preserving brain health by any major health organization and regulatory 
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agencies have not given any positive opinions for nutraceuticals or supplements to improve 
brain function during aging or neurodegeneration. Thus, hardly surprisingly nutraceutical as a 
commonly used in marketing term has no regulatory definition. There is little financial 
incentive for the pharmaceutical industry to progress this area, so a logical course of action 
would seem to be the participation of companies (loosely grouped under the industrial banner 
of natural health and wellbeing) involved in the provision of complementary medicines. The 
challenge for the community must be to work towards randomized placebo-controlled trials 
that will be the gold standard to confirm the effect of nutraceuticals on brain function. 
However, such trials may be impossible to conduct for nutraceuticals targeted to alleviate 
brain aging and cognitive decline, where subtle effects might add up over decades and be 
strongly influenced by individual differences in diet and nutrition. One finds in many 
published articles the concept that the interactions among various classes of chemicals 
present in foods may contribute to their potent “nutraceutical actions”. In fact Joseph et al. 
(1998) used the expression “the whole is more than the sum of its parts”.  
 
Despite the forgoing sentiments about the need for properly conducted clinical trials and 
regulation the story is not all doom and gloom. The prospect of future success in the field of 
neuro-nutraceuticals continues to capture the imagination of many neuroscientists. With 
stunning advances in neuroscience in the 21st century, there has been a remarkable growth in 
the identification of targets that provide therapeutic benefit in degenerative conditions, and 
neurodevelopmental, psychological and psychiatric disorders. Since many natural products 
used in traditional medicine have long been known to exert beneficial actions on diverse 
brain functions and often the active principles have been identified, nutraceutricals are 
potentially ripe for the plucking in terms of entering the developmental drug pipeline. 
Certainly there is also case for high throughput screening at identified targets using modern 
technologies. The work reported here with quercetin, curcumin, fisetin, allicin and 
oxymatrine represents important advances and indicates that naturally occurring molecules 
can be beneficial to both the young and aged brain, and that they have actions that ultimately 
can be directed to aid in the improvement of cognition and in the management of debilitating 
brain pathologies. 
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Figure legend 
 
Fig. 1. Potential benefit of nutraceuticals on brain dysfunction. Nutraceuticals are food, or 
part of a food, and will give health benefits in addition to nutrition to provide better health 
and/or minimize pathological effects. Molecules contained therein provide medicinal value, 
and bridge the gap between food and prescribed medicine. Nutraceuticals provide more than 
nutritional value, and the synergistic actions of certain ingredients subtly influence key 
cellular signalling that favours improved neuronal function. Medicine is an independent 
molecule designed to have specific action at one target, but at higher doses and over long-
term use these molecules could adversely affect normal cellular functions, possibly leading to 
cellular toxicity. Such events may exacerbate mechanisms (dysfunctional bioenergetics, 
oxidative stress, DNA damage, inflammation, neuronal injury) that contribute to normal 
ageing and cellular crises, and ultimately brain damage. Nutritious food containing molecules 
with medicinal value can alleviate these disruptive mechanisms by correcting deranged 
cellular signalling, and thus nutraceuticals provide the added value of helping to repair 
cellular damage, thereby improving brain health. 
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